AI Article Synopsis
- Monkeypox has seen outbreaks outside its original West African regions since May 2022, prompting a study on the effectiveness of tecovirimat, a drug estimated to be effective against both smallpox and monkeypox.
- This nationwide study involves patients taking tecovirimat for 14 days and will compare results from those receiving the treatment versus a control group that only gets supportive care, measuring outcomes like viral load and adverse effects.
- Participants will be financially supported through research funding, and all ethical guidelines, including informed consent, will be followed; findings will be shared in academic publications and conferences.
Article Abstract
Introduction: Monkeypox was originally endemic locally in West Africa; however, outbreaks in non-endemic countries have been recognised since May 2022. The effectiveness of tecovirimat has been estimated against smallpox, which belongs to the same genus as monkeypox. Thus, tecovirimat is expected to be effective against monkeypox. This study aims to evaluate the efficacy and safety of oral tecovirimat therapy for patients with smallpox and monkeypox and to prepare a scheme for oral tecovirimat use in Japan.
Methods And Analysis: This nationwide, multicentre, non-randomised, open-label, double-arm study will involve viral examination of the blood, throat swabs, urine and skin lesions, performed periodically. Participants will freely decide whether to participate in an administered group (supportive treatment plus oral tecovirimat) or a non-administered group (only supportive treatment). Tecovirimat will be administered for 14 days. To ensure that financial problems do not preclude participation in the study, the research fund will cover the cost of tecovirimat and basic hospitalisation fees. The primary endpoint is the percentage of patients with negative PCR results (cycle threshold value ≥40) for skin lesion specimens at 14 days after inclusion in the study. Secondary endpoints include mortality at 14 and 30 days, viral load in each sample, duration of fever and adverse events. The sample size is estimated to be 50 patients with monkeypox or smallpox.
Ethics And Dissemination: Written informed consent will be obtained from all participants. This study was approved by the Certified Review Board of National Center for Global Health and Medicine and published in the Japan Registry of Clinical Trials. The results of this study will be published in peer-reviewed journals and/or in presentations at academic conferences.
Trial Registration Number: jRCTs031220169.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10394549 | PMC |
| http://dx.doi.org/10.1136/bmjopen-2022-069550 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Fatal borealpox in an immunosuppressed patient treated with antivirals and vaccinia immunoglobulin - Alaska, 2023.
Clin Infect Dis
November 2024
Section of Epidemiology, Alaska Division of Public Health, Anchorage, Alaska, USA.
Background: Borealpox virus (BRPV, formerly known as Alaskapox virus) is a zoonotic member of the Orthopoxvirus genus first identified in a person in 2015. In the six patients with infection previously observed BRPV involved mild, self-limiting illness. We report the first fatal BRPV infection in an immunosuppressed patient.
View Article and Find Full Text PDFA robust mouse model of HPIV-3 infection and efficacy of GS-441524 against virus-induced lung pathology.
Nat Commun
September 2024
KU Leuven Department of Microbiology, Immunology and Transplantation, Rega Institute for Medical Research, Virology, Antiviral Drug & Vaccine Research Group, Leuven, Belgium.
Article Synopsis
- HPIV-3 causes serious respiratory infections, and current small-animal models for studying it are inadequate, but AG129 mice effectively replicate the virus's effects.
- Research showed that HPIV-3 targets specific lung cells and leads to significant lung damage, but does not spread between cohabitating infected and non-infected mice.
- Treatment with GS-441524, a remdesivir component, decreased the virus in the lungs and improved lung health, suggesting AG129 mice are useful for testing new treatments and preventative measures for HPIV-3 in humans.
Endothelial Involvement in Monocular Mpox Keratitis: In Vivo Confocal Microscopy Approach.
Cornea
August 2024
Centro de Oftalmología Barraquer, Barcelona, Spain.
Article Synopsis
- The study investigates a case of Mpox virus keratitis in a 35-year-old man using in vivo confocal microscopy (IVCM), detailing the clinical symptoms and endothelial involvement.
- The patient experienced significant eye issues like pain, redness, and low visual acuity after a 6-week Mpox infection, with IVCM findings indicating inflammation and altercations in the corneal endothelial layer.
- The results underscore the importance of IVCM for early identification of endotheliitis related to Mpox, suggesting that patients with corneal epithelial damage are at risk for this condition before developing severe keratitis.
Challenges in Managing Treatment-Resistant Mpox Complicated by Severe Superinfection.
Open Forum Infect Dis
April 2024
Division of Infectious Diseases, Department of Medicine, University of Florida, Jacksonville, Florida, USA.
Though typically self-limiting, severe mpox infections have been treated with antiviral medications, most notably tecovirimat. Various reports exist of mpox progression despite tecovirimat treatment. Treatment resistance can be due to acquired mpox strain mutations, most often occurring in an immunocompromised host.
View Article and Find Full Text PDFPersistent and Severe Mpox Keratitis Despite Systemic and Topical Treatment.
Cornea
June 2024
Department of Ophthalmology, La Paz University Hospital, Madrid, Spain.
Purpose: The purpose of this study was to report a case of peripheral ulcerative keratitis in a patient diagnosed with corneal polymerase chain reaction (PCR) and a positive mpox culture.
Methods: This is a case report.
Results: An immunocompetent 54-year-old man was diagnosed with conjunctivitis in his left eye 15 days after being diagnosed with mucocutaneous monkeypox.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!